Iterum Therapeutics Files 8-K on Financials

TL;DR

Iterum Therapeutics dropped an 8-K detailing their latest financial and operational results. Check it out!

AI Summary

Iterum Therapeutics plc filed an 8-K on March 29, 2024, reporting on its results of operations and financial condition as of March 28, 2024. The filing includes financial statements and exhibits, providing an update on the company's financial status and operational performance.

Why It Matters

This 8-K filing provides crucial updates on Iterum Therapeutics' financial health and operational performance, which are key factors for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Iterum Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial reporting.

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• March 28, 2024 (date) — Date of earliest event reported
• March 29, 2024 (date) — Filing date
• Ireland (location) — State of incorporation
• Dublin 2 (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar

Filing Documents

• itrm-20240328.htm (8-K) — 37KB
• itrm-ex99_1.htm (EX-99.1) — 236KB
• img185001215_0.jpg (GRAPHIC) — 8KB
• 0000950170-24-038414.txt ( ) — 414KB
• itrm-20240328.xsd (EX-101.SCH) — 26KB
• itrm-20240328_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 28, 2024, Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. The information in this current report on Form 8-K, including the press release attached as Exhibit 99.1 hereto, is being furnished, but shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Iterum Therapeutics plc, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. 99.1 Press Release of Iterum Therapeutics plc, dated March 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: March 28, 2024 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR